세계의 결합 백신 시장 보고서(2023년)

“Conjugate Vaccine Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The conjugate vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
• 2) By Pathogen: Bacterial; Viral
• 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
• 4) By Patient: Pediatric; Adults
• 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
• Companies Mentioned: Sanofi S.A; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the conjugate vaccine market are: Sanofi S.A, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., and Bio-Med Pvt. Ltd.

The global conjugate vaccine market is expected to grow from $14.69 billion in 2022 to $16.77 billion in 2023 at a compound annual growth rate (CAGR) of 14.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The conjugate vaccine market is expected to reach $27.22 billion in 2027 at a CAGR of 12.9%.

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

North America was the largest region in the conjugate vaccine market in 2022. The regions covered in conjugate vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines are vaccines that contain a single conjugated antigen, typically targeting a specific pathogen or strain, and are used to prevent infections caused by bacteria that have a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. They are developed with such bacterial and viral pathogens for the treatment of various diseases, including pneumococcal, influenza, meningococcal, and typhoid, for pediatric and adult patients used by hospitals, clinics, homecare settings, and others.

The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body's defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, according to the Historical national influenza vaccination coverage 2020-2022, published by the National Centre for Immunization Research and Surveillance, an Australia-based research organization, historical influenza vaccine coverage at the end of 2022 by 15 - < 50 years age group was 29.5%, an increase from 22.8% recorded in 2021. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.

Innovation in conjugate vaccines is a key trend gaining popularity in the conjugate vaccine market. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

In August 2022, GSK, a UK-based company engaged in pharmaceutical and biotechnology products, acquired Affinivax Inc. for $2.1 billion. With this acquisition, GSK aims to build a strong portfolio of specialty medicines and vaccines and strengthen its position in advanced pneumococcal vaccines, including AFX3772. Affinivax is a US-based biotechnology company specializing in conjugate vaccine development.

The countries covered in the conjugate vaccine market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Conjugate Vaccine Market
• 4.2. Ukraine-Russia War Impact On Conjugate Vaccine Market
• 4.3. Impact Of High Inflation On Conjugate Vaccine Market

5. Conjugate Vaccine Market Size And Growth

• 5.1. Global Conjugate Vaccine Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Conjugate Vaccine Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Conjugate Vaccine Market Segmentation

• 6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccine
• 6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Bacterial
• Viral
• 6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Pneumococcal
• Influenza
• Meningococcal
• Typhoid
• 6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Pediatric
• Adults
• 6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• Other End-Users

7. Conjugate Vaccine Market Regional And Country Analysis

• 7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

• 8.1. Asia-Pacific Conjugate Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Conjugate Vaccine Market

• 9.1. China Conjugate Vaccine Market Overview
• 9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Conjugate Vaccine Market

• 10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Conjugate Vaccine Market

• 11.1. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Conjugate Vaccine Market

• 12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Conjugate Vaccine Market

• 13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Conjugate Vaccine Market

• 14.1. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Conjugate Vaccine Market

• 15.1. Western Europe Conjugate Vaccine Market Overview
• 15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Conjugate Vaccine Market

• 16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Conjugate Vaccine Market

• 17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Conjugate Vaccine Market

• 18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Conjugate Vaccine Market

• 19.1. Eastern Europe Conjugate Vaccine Market Overview
• 19.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Conjugate Vaccine Market

• 20.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Conjugate Vaccine Market

• 21.1. North America Conjugate Vaccine Market Overview
• 21.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Conjugate Vaccine Market

• 22.1. USA Conjugate Vaccine Market Overview
• 22.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Conjugate Vaccine Market

• 23.1. South America Conjugate Vaccine Market Overview
• 23.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Conjugate Vaccine Market

• 24.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Conjugate Vaccine Market

• 25.1. Middle East Conjugate Vaccine Market Overview
• 25.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Conjugate Vaccine Market

• 26.1. Africa Conjugate Vaccine Market Overview
• 26.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Conjugate Vaccine Market Competitive Landscape And Company Profiles

• 27.1. Conjugate Vaccine Market Competitive Landscape
• 27.2. Conjugate Vaccine Market Company Profiles
  • 27.2.1. Sanofi S.A
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Pfizer Inc.
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Merck & Co. Inc.
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. GlaxoSmithKline plc
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Bharat Biotech International Limited
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Conjugate Vaccine Market

29. Conjugate Vaccine Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer